Atea Pharmaceuticals, Inc.
AVIR
$3.10
$0.010.16%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 66.01M | 48.06M | 51.72M | 54.26M | 49.69M |
| Gross Profit | -66.01M | -48.06M | -51.72M | -54.26M | -49.69M |
| SG&A Expenses | 39.10M | 42.93M | 46.08M | 48.85M | 47.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 161.19M | 147.07M | 141.07M | 171.84M | 165.44M |
| Operating Income | -161.19M | -147.07M | -141.07M | -171.84M | -165.44M |
| Income Before Tax | -146.19M | -135.27M | -138.59M | -167.46M | -172.96M |
| Income Tax Expenses | 831.00K | 861.00K | 897.00K | 925.00K | 1.05M |
| Earnings from Continuing Operations | -147.03 | -136.13 | -139.49 | -168.39 | -174.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -147.03M | -136.13M | -139.49M | -168.39M | -174.01M |
| EBIT | -161.19M | -147.07M | -141.07M | -171.84M | -165.44M |
| EBITDA | -160.77M | -146.65M | -140.66M | -171.42M | -165.03M |
| EPS Basic | -1.78 | -1.61 | -1.65 | -2.00 | -2.07 |
| Normalized Basic EPS | -1.08 | -0.93 | -0.87 | -1.09 | -1.03 |
| EPS Diluted | -1.78 | -1.61 | -1.65 | -2.00 | -2.07 |
| Normalized Diluted EPS | -1.08 | -0.93 | -0.87 | -1.09 | -1.03 |
| Average Basic Shares Outstanding | 332.42M | 337.79M | 338.30M | 337.06M | 336.03M |
| Average Diluted Shares Outstanding | 332.42M | 337.79M | 338.30M | 337.06M | 336.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |